Rejected petition Debate compulsory licensing of Remdesivir in the UK with view to manufacture.

Consider the compulsory licensing of Remdesivir in the UK under WTO TRIPS agreement. Due to national emergency caused by Covid-19. Supply to be non-profit under the terms.

More details

Remdesivir is one of only two efficacious Covid-19 medicines. The US has achieved monopoly of this drug for the next quarter. Manufacturing of this pharmaceutical in the UK will therefore save lives. Alternatively, purchase may be achieved under WTO terms overseas under TRIPS agreement.

This petition was rejected

Why was this petition rejected?

It’s about something that the UK Government or Parliament is not directly responsible for.

The licensing of drugs for medical treatment is subject to an independent process conducted by the Medicines and Healthcare products Regulatory Agency (MHRA), so this decision is a matter for the MHRA, not the Government or House of Commons.

The Government has announced that, following a positive scientific opinion by the Medicines and Healthcare products Regulatory Agency under the Early Access to Medicines Scheme (EAMS), selected NHS patients will be able to access coronavirus treatment remdesivir: https://www.gov.uk/government/news/selected-nhs-patients-to-access-coronavirus-treatment-remdesivir

We only reject petitions that don’t meet the petition standards.

Date submitted 30 June 2020
Get petition data (json format)

About petition data

The data shows the number of people who have signed the petition by country as well as in the constituency of each Member of Parliament. This data is available for all petitions on the site. It is not a list of people who have signed the petition. The only name that is shared on the site is that of the petition creator.